(VIANEWS) - Peabody Energy Corporation (BTU), Genmab (GMAB), Atlanticus Holdings Corporation (ATLC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Peabody Energy Corporation (BTU)
90.1% sales growth and 63.92% return on equity
Peabody Energy Corporation engages in coal mining business in the United States, Japan, Taiwan, Australia, China, India, Vietnam, South Korea, and internationally. The company operates through Seaborne Thermal Mining, Seaborne Metallurgical Mining, Powder River Basin Mining, and Other U.S. Thermal Mining segments. It is involved in mining, preparation, and sale of thermal coal primarily to electric utilities; mining bituminous and sub-bituminous coal deposits; and mining metallurgical coal, such as hard coking coal, semi-hard coking coal, semi-soft coking coal, and pulverized coal injection coal. The company supplies coal primarily to electricity generators, industrial facilities, and steel manufacturers. As of December 31, 2020, it owned interests in 17 coal mining operations located in the United States and Australia; and had approximately 3.0 billion tons of proven and probable coal reserves and approximately 450,000 acres of surface property through ownership and lease agreements. The company also engages in direct and brokered trading of coal and freight-related contracts, as well as provides transportation-related services, which involve financial derivative contracts and physical contracts. Peabody Energy Corporation was founded in 1883 and is headquartered in St. Louis, Missouri.
Earnings per Share
Peabody Energy Corporation's trailing 12 months EPS is $8.4.
PE Ratio
Peabody Energy Corporation's trailing 12-month price-to-earnings ratio is 3.25. The purchaser of the shares is therefore investing $3.25 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability and shareholder equity ratio, was 63.92%.Earnings Before Interest, Taxes, Depreciation, and Amortization
Peabody Energy Corporation's EBITDA is 6.91.
Volume
Today's last reported volume for Peabody Energy Corporation is 555978 which is 88.1% below its average volume of 4675540.
2. Genmab (GMAB)
31.8% sales growth and 17.71% return on equity
Genmab A/S is a Danish company that develops and markets antibody therapies for cancer treatment. DARZALEX is a monoclonal human antibody that can be used to treat multiple myeloma. Teprotumumumab can also be used for treatment of the thyroid eye disorder. Ofatumurnab (a human monoclonal anti-body for chronic lymphocyticleukemia (CLL), multiple sclerosis) and Amivantamab (for advanced, metastatic, or esophageal, cancers and NSCLC) are available. Daratumumab is used to treat MM and non-MM blood tumors and AL Amyloidosis. The company also produces products. Phase 2 includes Teclistamab to treat vaso-occlusive crisis; Camidanlumab tesirine for treatment of hodgkin lymphoma; JNJ-64407564 for treatment of MM; PRV-015 to treat celiac disorder; Mim8 to treat haemophilia; and Lu AF82422 to treat multiple system atrophy. It also has 20 preclinical trials. Seagen Inc. has granted the company a collaboration and commercial license to develop tisotumab. The company also has a partnership agreement with CureVac AG to research and develop differentiated mRNA-based antibodies products. AbbVie is responsible for developing epcoritamab. There are collaborations with BioNTech, Janssen, Novo Nordisk A/S, Bolt Biotherapeutics, Inc. Genmab A/S was established in 1999. Its headquarters are in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.66.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 58.56. Meaning, the purchaser of the share is investing $58.56 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.71%.Volume
Genmab's current reported volume is 171930, which is 74.19% lower than its average volume (666331).
Sales Growth
Genmab's sales growth is 26.8% for the ongoing quarter and 31.8% for the next.
Yearly Top and Bottom Value
Genmab's stock is valued at $38.72 at 10:22 EST, way under its 52-week high of $47.50 and way above its 52-week low of $26.19.
3. Atlanticus Holdings Corporation (ATLC)
30% sales growth and 37.93% return on equity
Atlanticus Holdings Corporation provides credit and related financial services and products to customers the United States. It operates in two segments, Credit as a Service, and Auto Finance. The Credit as a Service segment originates a range of consumer loan products, such as private label and general purpose credit cards originated by lenders through various channels, including retail and healthcare, direct mail solicitation, digital marketing, and partnerships with third parties; and offers credit to their customers for the purchase of various goods and services, including consumer electronics, furniture, elective medical procedures, healthcare, educational services, and home-improvements by partnering with retailers and service providers. In addition, it offers loan servicing, such as risk management and customer service outsourcing for third parties; and engages in testing and investment activities in consumer finance technology platforms. The Auto Finance segment purchases and/or services loans secured by automobiles from or for a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here, and used car business. This segment also provides floor plan financing and installment lending products. Further, the company invests in and services portfolios of credit card receivables. Atlanticus Holdings Corporation was founded in 1996 and is headquartered in Atlanta, Georgia.
Earnings Per Share
As for profitability, Atlanticus Holdings Corporation has a trailing twelve months EPS of $6.94.
PE Ratio
Atlanticus Holdings Corporation has a trailing twelve months price to earnings ratio of 4.3. Meaning, the purchaser of the share is investing $4.3 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 37.93%.Annual Top and Bottom Value
At 10:22 EST Atlanticus Holdings Corporation stock was valued at $29.85, which is way below its 52 week high of $72.38 but well above its 52 week low of $23.15.
Sales Growth
Atlanticus Holdings Corporation saw a 34.2% increase in sales for its current quarter, and a 30% rise for the next.
Growth Estimates Quarters
For the current quarter, the company expects a decline of 29.6% in growth and for the next quarter, a decrease of 28.1% respectively.4. Bio-Techne Corp (TECH)
8.7% sales growth and 16.08% return on equity
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Earnings Per Share
As for profitability, Bio-Techne Corp has a trailing twelve months EPS of $4.4.
PE Ratio
Bio-Techne Corp has a trailing twelve months price to earnings ratio of 18.36. Meaning, the purchaser of the share is investing $18.36 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.08%.Sales Growth
Bio-Techne Corp's sales growth is 7.5% for the present quarter and 8.7% for the next.
Revenue Growth
Year-on-year quarterly revenue growth grew by 11.3%, now sitting on 1.11B for the twelve trailing months.